Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes (from the TRACER Trial)

The American Journal of Cardiology
Jan H CornelRobert A Harrington

Abstract

We evaluated the interaction between protease-activated receptor-1 antagonist vorapaxar and concomitant glycoprotein (GP) IIb/IIIa receptor inhibitors in patients with non-ST-segment elevation acute coronary syndromes who underwent PCI. In Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome trial, 12,944 patients with non-ST-segment elevation acute coronary syndromes were randomized to vorapaxar or placebo. Administration of GP IIb/IIIa receptor inhibitors was allowed at the treating physician's discretion. We investigated whether use of GP IIb/IIIa receptor inhibitors modified vorapaxar's effect on non-coronary artery bypass grafting (CABG)-related bleeding at 7 days and ischemic events at 30 days. In total, 7,455 patients underwent PCI during index hospitalization. Of these, 2,023 patients (27.1%) received inhibitors and 5,432 (72.9%) did not. Vorapaxar was associated with a numerically higher rate of non-CABG-related moderate/severe Global Use of Strategies to Open Occluded Arteries (GUSTO) bleeding at 7 days compared with placebo in those who did (1.3% vs 1.0%) and did not (0.6% vs 0.4%) receive GP IIb/IIIa receptor inhibitors. Ischemic end point rates at 30 days were not significantly lower...Continue Reading

References

Oct 29, 2005·The American Journal of Cardiology·Sunil V RaoRobert A Harrington
Feb 21, 2006·Journal of the American College of Cardiology·Sunil V RaoRobert A Harrington
Aug 16, 2006·Circulation·John W EikelboomSalim Yusuf
Feb 15, 2007·JAMA : the Journal of the American Medical Association·Gregg W StoneUNKNOWN ACUITY Investigators
Apr 1, 2009·The New England Journal of Medicine·Robert P GiuglianoUNKNOWN EARLY ACS Investigators
May 22, 2009·The New England Journal of Medicine·Shamir R MehtaUNKNOWN TIMACS Investigators
Nov 15, 2011·The New England Journal of Medicine·Pierluigi TricociUNKNOWN TRACER Investigators
Dec 14, 2011·Current Cardiology Reports·Sergio LeonardiKenneth W Mahaffey

❮ Previous
Next ❯

Citations

Nov 13, 2015·Expert Review of Cardiovascular Therapy·Udaya S TantryPaul A Gurbel
Sep 26, 2015·Future Cardiology·Francesco FranchiDominick J Angiolillo
Feb 1, 2017·Expert Opinion on Drug Metabolism & Toxicology·Jose-Angel Perez-RiveraPablo Ruiz-Perez
Apr 21, 2020·Future Cardiology·Udaya S TantryPaul A Gurbel
Jul 12, 2016·Coronary Artery Disease·Leo UngarKenneth W Mahaffey
Dec 26, 2018·Expert Opinion on Investigational Drugs·Srikanth YandrapalliWilbert S Aronow
Jul 12, 2019·Research and Practice in Thrombosis and Haemostasis·Patricia P WadowskiThomas Gremmel

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.